Basic Information
| LncRNA/CircRNA Name | FLJ22763 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot analysis, in vitro knockdown, etc. |
| Sample | cell lines(SGC-7901, MGC-803, BGC-823, MKN-28 and GES-1 cells) |
| Expression Pattern | down-regulated |
| Function Description | FLJ22763, a novel lncRNA, had significantly lower expression in GC tissues. Decreased expression of FLJ22763 was positively correlated with a lower-level histological grade and the depth of invasion. The ectopic expression of lncRNA FLJ22763 significantly suppressed the biological malignant behavior of GC cells and inhibited xenograft tumor growth (both P < 0.001). Notably, FLJ22763 displayed a considerable predictive effect in the prognosis of GC (log-rank, P=0.003). Furthermore, we found that FLJ22763 was negatively associated with ACLY, regulating the mRNA and protein levels of ACLY. Our findings suggested that FLJ22763 may act as a suppressor gene to regulate the expression of ACLY, and its down-expression may be an independent prognostic factor in patients with GC. |
| Pubmed ID | 30716442 |
| Year | 2019 |
| Title | Long non-coding RNA FLJ22763 is involved in the progression and prognosis of gastric cancer. |
External Links
| Links for FLJ22763 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |